Allergy Therapeutics (AGY): Corp Regulatory update – Phase III birch allergy trial | Elixirr (ELIX): Corp Thriving on change | Telit (TCM): Corp Earnings well protected during COVID slowdown | Tracsis (TRCS): Corp Worst case avoided
09 Jul 2020
Morning Note – 9 July 2020
Allergy Therapeutics plc (AGY:LON), 20.4 | Tracsis plc (TRCS:LON), 650 | Telit Communications S.p.A. (TCM:LON), 197 | Elixirr International Plc (ELIX:LON), 329
-
-
-
Andrew Darley | Guy Hewett | Lorne Daniel | Mark Brewer | Michael Hill | Hayley Palmer | Arshad Ahad
-
7 pages
-


Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Morning Note – 9 July 2020
Allergy Therapeutics plc (AGY:LON), 20.4 | Tracsis plc (TRCS:LON), 650 | Telit Communications S.p.A. (TCM:LON), 197 | Elixirr International Plc (ELIX:LON), 329
- Published:
09 Jul 2020 -
Author:
Andrew Darley | Guy Hewett | Lorne Daniel | Mark Brewer | Michael Hill | Hayley Palmer | Arshad Ahad -
Pages:
7 -
Allergy Therapeutics (AGY): Corp Regulatory update – Phase III birch allergy trial | Elixirr (ELIX): Corp Thriving on change | Telit (TCM): Corp Earnings well protected during COVID slowdown | Tracsis (TRCS): Corp Worst case avoided